Skip to main content
TipRanks
Go Ultimate75% OFF

TransThera Sciences (Nanjing). Inc. (2617) AI Stock Analysis

5 Followers
HK:2617

TransThera Sciences (Nanjing). Inc.

(HKEX:2617)

Select Model
Rating:43Neutral
Price Target:HKD 7.00▲(0.72% Upside)
Action:reiterated
Date:11/17/26

The score is primarily constrained by persistent losses, heavy cash burn, negative valuation metrics, and broadly bearish technical trends. The company’s low leverage and equity-funded balance sheet provide meaningful support, but they do not yet offset the risks of a pre-revenue, cash-consuming biotech.

Positive Factors
Low LeverageVery low debt relative to equity limits refinancing and interest-rate exposure, giving the company greater financial flexibility while it develops its pipeline. This conservative capital structure is a durable support compared with a heavily leveraged biotechnology business facing extended development timelines.
Negative Factors
No Recent RevenueZero revenue in the two most recent annual periods shows that the pipeline has not yet translated into commercial sales. This leaves the company without an operating revenue base to absorb research costs, support recurring cash generation, or demonstrate near-term operating leverage.

TransThera Sciences (Nanjing). Inc. (2617) vs. iShares MSCI Hong Kong ETF (EWH)

-100%-75%-50%-25%0%25%HK:2617-96.60%EWH+9.93%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 2.65B
Dividend Yield
―
Average Volume (3M)
4.41M
Price to Earnings (P/E)
-5.8
Beta (1Y)
2.68
Revenue Growth
―
EPS Growth
-13.19%
Country
Hong Kong
Employees
132
Sector
General
Sector Strength
55
Industry
Biotechnology

TransThera Sciences (Nanjing). Inc. Business Overview & Revenue Model

Company Description

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a...

TransThera Sciences (Nanjing). Inc. Financial Statement Overview

Summary

Very weak income and cash-flow profiles reflect no meaningful revenue, persistent losses, and substantial cash burn. A low-debt, largely equity-funded balance sheet provides an important offset, but equity and assets are declining.

Income Statement

18Very Negative

Balance Sheet

72Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2020
Income Statement
Total Revenue34.97M001.18M124.00K61.76M
Gross Profit30.68M001.18M124.00K0
EBITDA-267.59M-290.82M-267.97M-413.42M8.55M-39.27M
Net Income-268.29M-295.96M-274.61M-344.12M-250.04M-80.72M
Balance Sheet
Total Assets987.24M545.91M629.60M887.09M1.35B344.94M
Cash, Cash Equivalents and Short-Term Investments925.22M489.14M572.53M838.17M1.11B279.34M
Total Debt5.61M1.65M4.37M4.81M3.04M490.74M
Total Liabilities109.26M129.53M104.57M103.91M111.04M578.87M
Stockholders Equity877.99M416.38M525.03M783.18M1.24B-233.94M
Cash Flow
Free Cash Flow-144.55M-253.68M-271.95M-331.12M-244.00M-76.61M
Operating Cash Flow-144.47M-253.51M-271.18M-319.33M-241.94M-66.68M
Investing Cash Flow108.03M-68.00M348.42M-186.94M26.98M-195.84M
Financing Cash Flow1.55M169.00M-4.87M15.76M240.45M311.48M

TransThera Sciences (Nanjing). Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price6.95

Price Trends

50DMA9.18Negative
100DMA9.88Negative
200DMA33.61Negative

Market Momentum

MACD-0.57Positive
RSI26.72Positive
STOCH3.28Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2617, the sentiment is Negative. The current price of 6.95 is below the 20-day moving average (MA) of 8.09, below the 50-day MA of 9.18, and below the 200-day MA of 33.61, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 26.72 is Positive, neither overbought nor oversold. The STOCH value of 3.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2617.

TransThera Sciences (Nanjing). Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

HK:2617 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:9995HK:999566NeutralHKD 48.71B7.43105.60%―292.84%―
HK:1548HK:154865NeutralHKD 67.32B-13.18-16.23%―53.48%-120.02%
HK:2696HK:269665NeutralHKD 23.70B23.2320.41%―32.63%8.74%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
HK:9688HK:968846NeutralHKD 23.58B-12.59-31.11%―0.28%8.30%
HK:2617HK:261743NeutralHKD 2.18B-5.76-40.84%――-13.19%
HK:1877HK:187741NeutralHKD 27.62B-63.59-7.23%―35.82%54.40%

* General Sector Average

Performance Comparison

0%100%200%HK:2617HK:1548HK:9688HK:9995HK:1877HK:2696Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:2617 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:2617TransThera Sciences (Nanjing). Inc.6.95-208.05-96.77%
HK:1548Genscript Biotech Corporation30.8414.9694.21%
HK:9688Zai Lab Ltd17.871.7911.13%
HK:9995RemeGen Co. Ltd. Class H60.85-24.10-28.37%
HK:1877Shanghai Junshi Biosciences Co., Ltd. Class H13.92-10.64-43.32%
HK:2696Shanghai Henlius Biotech, Inc. Class H43.46-24.14-35.71%

TransThera Sciences (Nanjing). Inc. Corporate Events

TransThera Wins HKEX Nod for H-Share Full Circulation Conversion

Nov 1, 2026

TransThera Sciences (Nanjing), Inc. has received approval from the Hong Kong Stock Exchange to list 44,971,128 converted H shares, which will be transformed from the same number of previously unlisted shares. These converted shares, held by 10 partic...

TransThera Sciences Advances Full Circulation Plan for H Shares After CSRC Filing

Oct 26, 2026

TransThera Sciences (Nanjing), Inc., a PRC-based biopharmaceutical company listed on the Hong Kong Stock Exchange, is pursuing capital market optimization by converting a portion of its domestic shares into H shares to improve liquidity. The company’...

TransThera launches national rollout of first-in-China cholangiocarcinoma drug Yochanra

Oct 22, 2026

TransThera Sciences (Nanjing), Inc. has begun nationwide commercialisation of its core oncology drug Yochanra (tinengotinib tablets) in China after securing conditional marketing approval for adults with unresectable advanced or metastatic cholangioc...

TransThera’s Tinengotinib Secures CSCO Guideline Placement for Advanced Biliary Tract Cancers

Sep 18, 2026

TransThera Sciences has announced that its self-developed multi-target kinase inhibitor YOCHANRA (tinengotinib) has been included as a Class II, Class 2A recommendation in the 2026 Chinese Society of Clinical Oncology guidelines for the diagnosis and...

TransThera Starts Phase II Trial of Tinengotinib Combo in Resistant Prostate Cancer

Sep 18, 2026

TransThera Sciences (Nanjing), Inc., a China-based biopharma company specializing in innovative oncology drugs, is developing tinengotinib, a multi-target kinase inhibitor aimed at solid tumors such as cholangiocarcinoma and prostate cancer. With exi...

TransThera Sciences Narrows Interim Loss as Revenue Emerges Amid Rising R&D Spend

Aug 26, 2026

TransThera Sciences (Nanjing), Inc. reported its unaudited interim results for the six months ended 30 June 2026, posting revenue of RMB35.46 million versus no revenue a year earlier and a gross profit of the same amount as no cost of sales was recor...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026